News
NMPA (China) approves Xenleta (lefamulin) in China for the treatment of community-acquired pneumonia in adults .- Sumitomo Pharma.
Sumitomo Pharma Chinese subsidiary received a notification from local regulators that Xenleta (lefamulin) was approved in China for the treatment of community-acquired pneumonia in adults.
The drug will be available in injection and tablet forms. The timeline for its release is still under consideration.
Xenleta is a pleuromutilin antibiotic discovered and developed by Ireland-based Nabriva Therapeutics. Having a novel mechanism of action, the drug is less likely to develop resistance or cross-resistance.
Condition: Infectious Diseases /CABP
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins